Drug profile · INN
diphenhydramine citrate
IBUPROFEN AND DIPHENHYDRAMINE CITRATE
diphenhydramine citrate (IBUPROFEN AND DIPHENHYDRAMINE CITRATE) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — diphenhydramine citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
diphenhydramine citrate (IBUPROFEN AND DIPHENHYDRAMINE CITRATE) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is diphenhydramine citrate?
diphenhydramine citrate (IBUPROFEN AND DIPHENHYDRAMINE CITRATE) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for diphenhydramine citrate?
IBUPROFEN AND DIPHENHYDRAMINE CITRATE is a marketed brand name for diphenhydramine citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of diphenhydramine citrate?
diphenhydramine citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.